Table 1.

Clinical efficacy data of randomized phase 2 studies of selumetinib in melanoma

Trial and regimen	N	Treatment setting	Overall response rate, %	P-value	Median progression-free survival, months	Hazard ratio (95% confidence interval), P-value	Median overall survival, months	Hazard ratio (95% confidence interval), P-value	Reference
Selumetinib versus temozolomide	104 versus 96	First-line	5.8 versus 9.4	NS	2.6 versus 2.7	1.07(0.86–1.32), 0.6	9.5 versus 12.3	1.35(0.95–1.93), 0.9	37
Selumetinib		First-line; BRAF V600EIK with two cohort (low versus high pAKT)		NS		NS		NS	38
Low pAKT	5		60		7.1		18
High pAKT	10		0		2.2		8
Selumetinib + dacarbazine versus dacarbazine	45 versus 46	First-line; BRAF V600	40 versus 26	0.081	5.6 versus 3	0.63 (0.47–0.84), 0.021	13.9 versus 10.5	0.93(0.67–1.28), 0.39	39
Selumetinib versus temozolomide	47 versus 49	First-line; advanced uveal melanoma	15 versus 0	NS	3.7 versus 1.6	0.46(0.3–0.71), <0.00l	10.8 versus 9.4	0.79(0.46–1.37), 0.4	40

Abbreviation: NS, not significant.